



08/27/07

1FW

Dkt. No. 29248/18

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant : Erik Buntinx  
Appl. No. : 10/725,965  
Filed : December 2, 2003  
For : METHOD OF TREATING MENTAL DISORDERS USING  
OF D4 AND 5-HT2A ANTAGONISTS, INVERSE AGONISTS  
OR PARTIAL AGONISTS  
Art Unit : 1617  
Examiner : Umamaheswari Ramachandran  
Customer No.: 1912

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

"Express Mail" mailing label No. EV 725836748 US  
Date of Deposit: August 24, 2007

I hereby certify that this paper or fee is being  
deposited with the United States Postal Service  
"Express Mail" service under 37 CFR 1.10 on the date  
indicated above and is addressed to the  
Commissioner for Patents, P.O. Box 1450, Alexandria,  
VA 22313-1450.

Name: Alan D. Miller

Signature: [Signature]

Sir:

This Supplemental Information Disclosure Statement (SIDS) is being filed  
to supplement the Information Disclosure Statement filed on April 10, 2007 and  
August 9, 2005 in connection with the subject application.

In accordance with the duty of disclosure under 37 C.F.R. §1.56, applicant  
would like to direct the Examiner's attention to the references that are listed on the  
attached form PTO/SB/08A-B. A copy of each non-U.S. patent documents is also  
attached. These references were cited in an Office Action issued on August 10, 2007 in

Applicant: Erik Buntinx  
Serial No.: 10/725,965  
Filed: December 2, 2003  
Page 2


connection with U.S. Patent Application No. 10/984,683 and an Office Action issued on May 3, 2007 in connection with U.S. Patent Application No. 10/803,793.

Applicant is submitting the subject Supplemental Information Disclosure Statement pursuant to 37 C.F.R. §1.97(b)(3) before the mailing of a first Office Action on the merits. Accordingly, no fee is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement. However, if any fee is required in connection with this submission or to maintain the pendency of the subject application, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 01-1785.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN LLP  
Attorneys for Applicant  
90 Park Avenue  
New York, New York 10016  
(212) 336-8000

Dated: August 24, 2007  
New York, New York

By   
Alan D. Miller, Reg. No. 42,889



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/725,965
				Filing Date	December 2, 2003
				First Named Inventor	Erik Buntinx
				Art Unit	1617
				Examiner Name	Umamaheswari Ramachandran
Sheet	2	of	2	Attorney Docket Number	29248/18

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	4	HUBBLE J P et al., entitled "Pre-clinical studies of pramipexole: clinical relevance," European Journal of Neurology Supplement, 2000, Vol. 7 (Suppl. 1), pp. 15-20.	
	5	SILVER D E et al., entitled "Initiating therapy for Parkinson's disease," Neurology, 1998, Vol. 50 (Suppl. 6), pp. S18-S22.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.